We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Age related illnesses such as cardiovascular disease and cancer have driven a global drugs boom that pushed worldwide pharmaceutical sales above $US600 billion ($835billion) for the first time last year.
At the urging of the Nigeria-based National Agency for Food and Drug Administration and Control (NAFDAC), 12 African countries have established the West African Drug Regulators Forum, an agency that will combat the sale of counterfeit drugs in the sub-Saharan region -- where the illegal trade has become a prevalent and dangerous problem.
Finasteride, a medication that treats hair loss in men, may also improve the condition in women when it is combined with oral contraceptives, according to a study published in the Archives of Dermatology, one of the annex publications of the Journal of the American Medical Association.
Researchers from the UK-based medical technology company Cambridge Biostability -- in accordance with the University of Cambridge and funded by a $2.6 million grant from the Department of Trade and Industry -- are working to develop a slow-release type of vaccine that would eliminate the need for booster shots.
Ethypharm India has signed an out-licensing and supply contract with Dubai-based Globalpharma to market 10-mg cetirizine tablets in the Gulf Cooperation Council (GCC) region -- an area that encompasses Saudi Arabia, Bahrain, Kuwait, Oman, Qatar and the United Arab Emirates.
Antares Pharma, Inc. today announced that total revenues for the quarter ended December 31, 2005 increased 3% to approximately $734,000 from approximately $716,000 for the same quarter in 2004.
Victhom Human Bionics Inc. "Victhom" is pleased to announce today the appointment of a group of outstanding world renowned urology specialists and scientists to its Clinical Advisory Board (CAB).
Tripos, Inc. has announced a chemistry collaboration with Abbott to design, synthesize and purify high-quality, novel, drug-like compounds to expand Abbott's compound file collection.
Mylan Laboratories Inc. announced today that the regular quarterly cash dividend of $.06 per share will be payable on April 17, 2006, to shareholders of record at the close of business on March 31, 2006.